Medicines for Malaria Venture, by year, 2023 prices
Note: products launched or entering MMV’s portfolio. Deaths averted are estimated for the 15 highest-burden countries each year. The study’s authors include MMV and UK government staff, and credit all benefits to MMV.
Source: Christen et al., The Lancet Global Health (2026)
| Year | Funding received ($m, 2023 prices) | Products launched | Deaths averted |
|---|---|---|---|
| 2000 | 29.9 | 0 | 0 |
| 2001 | 50.1 | 0 | 0 |
| 2002 | 32.5 | 0 | 0 |
| 2003 | 61.2 | 0 | 0 |
| 2004 | 76.3 | 0 | 0 |
| 2005 | 114.1 | 0 | 0 |
| 2006 | 71.1 | 0 | 0 |
| 2007 | 173.9 | 0 | 0 |
| 2008 | 118.2 | 1 | 0 |
| 2009 | 85.9 | 0 | 0 |
| 2010 | 116.0 | 1 | 0 |
| 2011 | 128.3 | 1 | 0 |
| 2012 | 103.7 | 1 | 19,525 |
| 2013 | 106.9 | 0 | 21,339 |
| 2014 | 126.2 | 1 | 85,357 |
| 2015 | 135.1 | 3 | 67,167 |
| 2016 | 97.2 | 0 | 106,688 |
| 2017 | 120.3 | 1 | 122,252 |
| 2018 | 89.8 | 2 | 139,248 |
| 2019 | 93.5 | 1 | 145,246 |
| 2020 | 108.8 | 0 | 193,922 |
| 2021 | 100.8 | 0 | 240,314 |
| 2022 | 81.3 | 0 | 235,464 |
| 2023 | 78.0 | 0 | 214,947 |